Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Apr;41(4):757–762. doi: 10.1128/aac.41.4.757

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.

M A Winters 1, R W Shafer 1, R A Jellinger 1, G Mamtora 1, T Gingeras 1, T C Merigan 1
PMCID: PMC163789  PMID: 9087484

Abstract

The genetic mechanisms of human immunodeficiency virus type 1 (HIV-1) resistance to dideoxyinosine (ddI) in vivo have been described based on data from primary HIV-1 isolates. To better define the spectrum of HIV-1 reverse transcriptase (RT) changes occurring during ddI therapy, we determined the genotype and ddI susceptibility of the RT gene of HIV RNA isolated from the plasma of 23 patients who had received 1 to 2 years (mean, 87 +/- 16 weeks) of ddI monotherapy. Population-based sequencing of plasma virus showed that 12 of 23 (52%) patients developed known ddI resistance mutations: L74V (7 patients), K65R (2 patients), L74V with M184V (3 patients), and L74V with K65R (1 patient). Five patients developed one or more known zidovudine resistance mutations (at codons 41, 67, 70, 215, and/or 219) during the study. Other amino acid substitutions were found, but only S68G and L210W occurred in more than one patient. Studies of sensitivity to ddI were performed on population-based recombinant-virus stocks generated by homologous recombination between a plasmid containing an HXB2 clone with the RT gene deleted and RT-PCR products of the RT genes from patients' plasma RNA. The sequences of the virus stocks produced by this procedure were typically identical to the sequence of the input PCR product from plasma RNA. Both an MT-2 cell-based culture assay and a cell-free virion-associated RT inhibition assay showed that viruses possessing an L74V and/or M184V mutation or a K65R mutation had reduced sensitivity to ddI. Viruses without these specific mutations had no change in sensitivity to ddI. The results presented here show that the spectrum of RT mutations in a population of patients on ddI monotherapy is more complex than previously described. The development of multiple mutational patterns, including those that confer resistance to other nucleoside analogs, highlights the complexity of using the currently available nucleoside analogs for antiretroviral therapy.

Full Text

The Full Text of this article is available as a PDF (196.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boucher C. A., Keulen W., van Bommel T., Nijhuis M., de Jong D., de Jong M. D., Schipper P., Back N. K. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother. 1996 Oct;40(10):2404–2409. doi: 10.1128/aac.40.10.2404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cox S. W., Albert J., Wahlberg J., Uhlén M., Wahren B. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. AIDS Res Hum Retroviruses. 1992 Jul;8(7):1229–1234. doi: 10.1089/aid.1992.8.1229. [DOI] [PubMed] [Google Scholar]
  3. Demeter L. M., Nawaz T., Morse G., Dolin R., Dexter A., Gerondelis P., Reichman R. C. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis. 1995 Dec;172(6):1480–1485. doi: 10.1093/infdis/172.6.1480. [DOI] [PubMed] [Google Scholar]
  4. Eron J. J., Chow Y. K., Caliendo A. M., Videler J., Devore K. M., Cooley T. P., Liebman H. A., Kaplan J. C., Hirsch M. S., D'Aquila R. T. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother. 1993 Jul;37(7):1480–1487. doi: 10.1128/aac.37.7.1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gao Q., Gu Z., Parniak M. A., Cameron J., Cammack N., Boucher C., Wainberg M. A. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jun;37(6):1390–1392. doi: 10.1128/aac.37.6.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gao W. Y., Agbaria R., Driscoll J. S., Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994 Apr 29;269(17):12633–12638. [PubMed] [Google Scholar]
  7. Gu Z., Arts E. J., Parniak M. A., Wainberg M. A. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760–2764. doi: 10.1073/pnas.92.7.2760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gu Z., Gao Q., Fang H., Salomon H., Parniak M. A., Goldberg E., Cameron J., Wainberg M. A. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1994 Feb;38(2):275–281. doi: 10.1128/aac.38.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gu Z., Gao Q., Li X., Parniak M. A., Wainberg M. A. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol. 1992 Dec;66(12):7128–7135. doi: 10.1128/jvi.66.12.7128-7135.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Holodniy M., Mole L., Margolis D., Moss J., Dong H., Boyer E., Urdea M., Kolberg J., Eastman S. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol. 1995 Jun;69(6):3510–3516. doi: 10.1128/jvi.69.6.3510-3516.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Katzenstein D. A., Hammer S. M., Hughes M. D., Gundacker H., Jackson J. B., Fiscus S., Rasheed S., Elbeik T., Reichman R., Japour A. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996 Oct 10;335(15):1091–1098. doi: 10.1056/NEJM199610103351502. [DOI] [PubMed] [Google Scholar]
  12. Kavlick M. F., Shirasaka T., Kojima E., Pluda J. M., Hui F., Jr, Yarchoan R., Mitsuya H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res. 1995 Oct;28(2):133–146. doi: 10.1016/0166-3542(95)00044-m. [DOI] [PubMed] [Google Scholar]
  13. Kojima E., Shirasaka T., Anderson B. D., Chokekijchai S., Steinberg S. M., Broder S., Yarchoan R., Mitsuya H. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis. 1995 May;171(5):1152–1158. doi: 10.1093/infdis/171.5.1152. [DOI] [PubMed] [Google Scholar]
  14. Kozal M. J., Kroodsma K., Winters M. A., Shafer R. W., Efron B., Katzenstein D. A., Merigan T. C. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994 Aug 15;121(4):263–268. doi: 10.7326/0003-4819-121-4-199408150-00005. [DOI] [PubMed] [Google Scholar]
  15. Kozal M. J., Shafer R. W., Winters M. A., Katzenstein D. A., Merigan T. C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993 Mar;167(3):526–532. doi: 10.1093/infdis/167.3.526. [DOI] [PubMed] [Google Scholar]
  16. Kusumi K., Conway B., Cunningham S., Berson A., Evans C., Iversen A. K., Colvin D., Gallo M. V., Coutre S., Shpaer E. G. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol. 1992 Feb;66(2):875–885. doi: 10.1128/jvi.66.2.875-885.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mayers D. L., Japour A. J., Arduino J. M., Hammer S. M., Reichman R., Wagner K. F., Chung R., Lane J., Crumpacker C. S., McLeod G. X. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother. 1994 Feb;38(2):307–314. doi: 10.1128/aac.38.2.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nijhuis M., Boucher C. A., Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques. 1995 Aug;19(2):178-80, 182. [PubMed] [Google Scholar]
  19. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S. A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411–1419. doi: 10.1093/infdis/171.6.1411. [DOI] [PubMed] [Google Scholar]
  21. Shafer R. W., Kozal M. J., Winters M. A., Iversen A. K., Katzenstein D. A., Ragni M. V., Meyer W. A., 3rd, Gupta P., Rasheed S., Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr;169(4):722–729. doi: 10.1093/infdis/169.4.722. [DOI] [PubMed] [Google Scholar]
  22. Shafer R. W., Winters M. A., Jellinger R. M., Merigan T. C. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis. 1996 Aug;174(2):448–449. doi: 10.1093/infdis/174.2.448. [DOI] [PubMed] [Google Scholar]
  23. Shirasaka T., Chokekijchai S., Yamada A., Gosselin G., Imbach J. L., Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1995 Nov;39(11):2555–2559. doi: 10.1128/aac.39.11.2555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Simmonds P., Zhang L. Q., McOmish F., Balfe P., Ludlam C. A., Brown A. J. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol. 1991 Nov;65(11):6266–6276. doi: 10.1128/jvi.65.11.6266-6276.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith M. S., Koerber K. L., Pagano J. S. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. J Infect Dis. 1993 Feb;167(2):445–448. doi: 10.1093/infdis/167.2.445. [DOI] [PubMed] [Google Scholar]
  26. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  27. Vartanian J. P., Meyerhans A., Asjö B., Wain-Hobson S. Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol. 1991 Apr;65(4):1779–1788. doi: 10.1128/jvi.65.4.1779-1788.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  29. Winters M. A., Tan L. B., Katzenstein D. A., Merigan T. C. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol. 1993 Nov;31(11):2960–2966. doi: 10.1128/jcm.31.11.2960-2966.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zhang D., Caliendo A. M., Eron J. J., DeVore K. M., Kaplan J. C., Hirsch M. S., D'Aquila R. T. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1994 Feb;38(2):282–287. doi: 10.1128/aac.38.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES